logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11684570 B1

PDFFull Text
Date of Patent:
Jun. 27, 2023

Filed:

Aug. 11, 2022

Pharmaceutical ophthalmic compositions

Applicants:

Novel Drug Solutions Llc, Randolph, NJ (US);

Eye Care Northwest, PA, Sparta, NJ (US);

Inventors:

Jeffrey T. Liegner, Boise, ID (US);

John Scott Karolchyk, Lake Hopatcong, NJ (US);

Bernard Covalesky, Randolph, NJ (US);

Richard Dilzer, Long Valley, NJ (US);

Kalian Peters, Flemington, NJ (US);

Assignees:

NOVEL DRUG SOULTIONS LLC, Randolph, NJ (US);

EYE CARE NORTHWEST, PA, Sparta, NJ (US);

Attorney:

Browdy and Neimark, PLLC

Primary Examiner:

Sarah Alawadi

Int. Cl.
CPC ...
A61K 9/48 (2006.01); A61K 31/196 (2006.01); A61K 31/573 (2006.01); A61K 31/58 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 47/22 (2006.01); A61K 47/38 (2006.01); A61K 9/00 (2006.01); A61K 31/4709 (2006.01); A61K 38/14 (2006.01); A61K 31/496 (2006.01); A61K 38/12 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0048 (2013.01); A61K 31/196 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/573 (2013.01); A61K 31/58 (2013.01); A61K 38/12 (2013.01); A61K 38/14 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/22 (2013.01); A61K 47/38 (2013.01);
Abstract

Pharmaceutical ophthalmic compositions are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), a combination of at least two solubilizing and suspending agents (of which one is a non-ionic polyoxyethlene-polyoxypropylene block copolymer), and a carrier. Methods for fabricating the compositions and using them are also described.

Find Patent Forward Citations

Loading…